Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. [electronic resource]
Producer: 20130628Description: 543-51 p. digitalISSN:- 1474-5488
- Aged
- Angiogenesis Inhibitors -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Biomarkers, Tumor -- blood
- Carboplatin -- administration & dosage
- Chi-Square Distribution
- Cisplatin -- administration & dosage
- Disease Progression
- Drug Administration Schedule
- Female
- Glutamates -- administration & dosage
- Guanine -- administration & dosage
- Humans
- Intention to Treat Analysis
- Kaplan-Meier Estimate
- Linear Models
- Lung Neoplasms -- blood
- Male
- Mesothelioma -- blood
- Mesothelioma, Malignant
- Middle Aged
- Multivariate Analysis
- Palliative Care
- Pemetrexed
- Pleural Neoplasms -- blood
- Proportional Hazards Models
- Thalidomide -- administration & dosage
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.